CO6741152A2 - Anticuerpos estables y solubles - Google Patents

Anticuerpos estables y solubles

Info

Publication number
CO6741152A2
CO6741152A2 CO13102367A CO13102367A CO6741152A2 CO 6741152 A2 CO6741152 A2 CO 6741152A2 CO 13102367 A CO13102367 A CO 13102367A CO 13102367 A CO13102367 A CO 13102367A CO 6741152 A2 CO6741152 A2 CO 6741152A2
Authority
CO
Colombia
Prior art keywords
antibodies
description
tnf
methods
stable
Prior art date
Application number
CO13102367A
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Original Assignee
Esbatech A Novartis Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44897558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6741152(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech A Novartis Co Llc filed Critical Esbatech A Novartis Co Llc
Publication of CO6741152A2 publication Critical patent/CO6741152A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción provee anticuerpos que se modifican para reducir propensión de agregación, y los métodos de producir dichos anticuerpos. La presente descripción también provee en particular anticuerpos scFv estables y solubles y fragmentos Fab específicos para TNF, que comprenden secuencias específicas de cadena ligera y cadena pesada que se optimizan para estabilidad, solubilidad, unión in vitro o in vivo de TNF, e inmunogenicidad baja. También se describen ácidos nucleicos, vectores y células huésped para expresión de los anticuerpos recombinantes de la descripción, métodos para aislarlos y el uso de dichos anticuerpos en la medicina.
CO13102367A 2010-10-22 2013-04-22 Anticuerpos estables y solubles CO6741152A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40579810P 2010-10-22 2010-10-22
US201161484749P 2011-05-11 2011-05-11

Publications (1)

Publication Number Publication Date
CO6741152A2 true CO6741152A2 (es) 2013-08-30

Family

ID=44897558

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13102367A CO6741152A2 (es) 2010-10-22 2013-04-22 Anticuerpos estables y solubles

Country Status (20)

Country Link
US (3) US8545849B2 (es)
EP (2) EP2630159B1 (es)
JP (4) JP6245985B2 (es)
KR (4) KR101635917B1 (es)
CN (2) CN103154033B (es)
AR (1) AR083495A1 (es)
AU (1) AU2011318179B2 (es)
BR (1) BR112013010949B1 (es)
CA (1) CA2814766C (es)
CL (2) CL2013001089A1 (es)
CO (1) CO6741152A2 (es)
CY (1) CY1119941T1 (es)
MX (2) MX351499B (es)
PL (1) PL2630159T3 (es)
RU (2) RU2015119440A (es)
TW (3) TWI584816B (es)
UA (1) UA111340C2 (es)
UY (1) UY33679A (es)
WO (1) WO2012051734A1 (es)
ZA (1) ZA201302537B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
ES2687245T3 (es) * 2011-10-20 2018-10-24 Esbatech - A Novartis Company Llc Anticuerpo estable de unión a antígenos múltiples
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
CN104582717B (zh) 2012-07-19 2018-03-13 雷德伍德生物科技股份有限公司 对cd22有特异性的抗体及其使用方法
UY35195A (es) 2012-12-18 2014-07-31 Novartis Ag Composiciones y metodos para proteinas de accion prolongada
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
JP2017531682A (ja) 2014-10-23 2017-10-26 アムジエン・インコーポレーテツド 医薬製剤の粘度低下
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN109311976A (zh) * 2016-06-20 2019-02-05 诺华股份有限公司 使用TNFα拮抗剂治疗干眼症的方法
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
CA3143478A1 (en) * 2019-07-09 2021-01-14 Tomer Hertz Antibodies with reduced immunogenicity
CN112786101A (zh) * 2019-11-07 2021-05-11 中国农业大学 热稳定性抗体的制备方法
US20230046834A1 (en) * 2019-11-21 2023-02-16 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE920716A1 (en) 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5213656A (en) 1991-12-04 1993-05-25 Gerber Scientific Products, Inc. Method of using a web for etching of a surface
KR100372119B1 (ko) * 1992-07-13 2003-06-28 유카리언, 인코포레이티드 지질화된단백질을경혈관적및세포내로전달하는방법
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
EP0938506B1 (en) * 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
US6470213B1 (en) 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
ES2225269T3 (es) 1999-12-28 2005-03-16 Esbatech Ag Intracuerpos con esqueleto definido que es estable en un ambiente reductor y aplicaciones de los mismos.
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP1506236B1 (en) 2002-05-22 2013-01-23 ESBATech - a Novartis Company LLC Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
EP1539947A4 (en) 2002-08-15 2006-09-06 Epitomics Inc HUMANIZED RABBIT ANTIBODIES
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7060225B2 (en) 2003-03-20 2006-06-13 Northeastern Ohio Universities College Of Medicine Self-contained assay device for rapid detection of biohazardous agents
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
JP2007520991A (ja) 2003-08-07 2007-08-02 エピトミクス インコーポレーティッド ウサギ単クローン抗体をヒト型化する方法
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2609999C (en) 2005-06-07 2017-05-30 Esbatech Ag Stable and soluble antibodies inhibiting tnf.alpha.
BRPI0622254A2 (pt) 2005-06-20 2011-08-09 Genentech Inc anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
US20100168393A1 (en) 2005-10-11 2010-07-01 Big Glucose Ltd. Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
EP2013236B1 (en) 2006-04-28 2015-06-17 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
EP1918302A3 (en) 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
DK2446904T3 (en) 2006-05-30 2015-07-27 Genentech Inc The anti-CD22 antibodies, immunoconjugates and their uses thereof
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
TWI609965B (zh) 2007-05-21 2018-01-01 艾爾德生物控股有限責任公司 新穎兔抗體人化方法以及經人化之兔抗體
CN103435696B (zh) * 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
PT2164961E (pt) * 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Manipulação baseada em sequências e otimização de anticorpos de cadeia única
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
JP5570998B2 (ja) * 2007-12-31 2014-08-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＴＮＦαに対する抗体
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
KR101790567B1 (ko) 2008-06-25 2017-10-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914319B8 (pt) * 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
EP2304033B1 (en) 2008-06-30 2016-09-07 ESBATech, an Alcon Biomedical Research Unit LLC Functionalized polypeptides
BRPI0915460A2 (pt) 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
MX2011010908A (es) 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anticuerpos anti-tnf-alfa y sus usos.
CN109293768A (zh) 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
FR2962651A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections fonctionnelles du tractus gastro-intestinal
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
BR112013010857A2 (pt) 2010-11-02 2016-09-13 Abbott Laboratoires imonoglubulinas de duplo domínio variável e usos das mesmas
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
WO2013063110A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17

Also Published As

Publication number Publication date
TW201920270A (zh) 2019-06-01
RU2015119440A3 (es) 2019-01-28
BR112013010949A2 (es) 2017-09-05
CN108359012B (zh) 2021-12-24
JP7148228B2 (ja) 2022-10-05
TWI652068B (zh) 2019-03-01
BR112013010949B1 (pt) 2022-02-01
KR101635917B1 (ko) 2016-07-04
PL2630159T3 (pl) 2018-04-30
CN103154033B (zh) 2018-04-24
JP2015193664A (ja) 2015-11-05
UY33679A (es) 2012-03-30
AR083495A1 (es) 2013-02-27
RU2558298C2 (ru) 2015-07-27
RU2013123266A (ru) 2014-11-27
TWI584816B (zh) 2017-06-01
AU2011318179A1 (en) 2013-05-02
CA2814766A1 (en) 2012-04-26
US20160176959A1 (en) 2016-06-23
US10570198B2 (en) 2020-02-25
MX2013004295A (es) 2013-06-05
RU2015119440A (ru) 2015-11-27
KR20190016137A (ko) 2019-02-15
JP6245985B2 (ja) 2017-12-13
EP3336105A1 (en) 2018-06-20
KR20170020558A (ko) 2017-02-22
KR20130138806A (ko) 2013-12-19
US8545849B2 (en) 2013-10-01
JP2013544078A (ja) 2013-12-12
CL2013001089A1 (es) 2014-03-07
JP2019054814A (ja) 2019-04-11
TW201221142A (en) 2012-06-01
TW201630623A (zh) 2016-09-01
JP2017184770A (ja) 2017-10-12
US9598487B2 (en) 2017-03-21
CA2814766C (en) 2017-11-28
TWI702230B (zh) 2020-08-21
EP2630159A1 (en) 2013-08-28
KR20160083970A (ko) 2016-07-12
US20120100153A1 (en) 2012-04-26
UA111340C2 (uk) 2016-04-25
AU2011318179B2 (en) 2014-12-11
CN108359012A (zh) 2018-08-03
US20130344086A1 (en) 2013-12-26
CL2015002735A1 (es) 2016-03-04
CN103154033A (zh) 2013-06-12
WO2012051734A1 (en) 2012-04-26
KR101947520B1 (ko) 2019-02-14
MX351499B (es) 2017-10-17
EP3336105B1 (en) 2020-11-04
EP2630159B1 (en) 2017-11-22
ZA201302537B (en) 2014-06-25
CY1119941T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
CO6741152A2 (es) Anticuerpos estables y solubles
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
AR127119A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CL2018000780A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
MX2007015280A (es) Anticuerpos estables y solubles que inhiben tnf-alfa.
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CL2012003610A1 (es) Proteina de union multivalente y multiespecífica que se une al factor de necrosis tumoral (tnf) y al inductor de apoptosis debil relacionado con el factor de necrosis tumoral (tweak); conjugado de union de dicha proteína; acido nucleico que la codifica; vector y célula que comprenden dicho acido nucleico; metodo para producir dicha proteína; composicion farmacéutica que comprende dicha proteína
MX363307B (es) Plataformas para suministro de antigenos.
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112013006699A2 (pt) vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
EA201301089A1 (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
WO2012162565A3 (en) Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
AR080680A1 (es) Proteinas de union a basigina
CY1115803T1 (el) Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα
WO2013162905A8 (en) Methods of producing and using regulatory b-cells